{
  "id": "mhgap#risk_safety_227145b2",
  "content": "3.1 Alcohol use disorders (ALC) 12\n3.2 Anxiety (ANX) 18\n3.3 Child and adolescent mental disorders (CAMH) 28\n3.4 Conditions related to stress (STR) 46\n3.5 Dementia (DEM) 50\n3.6 Depression (DEP) 58\n3.7 Drug use disorders (DRU) 64\n3.8 Epilepsy and seizures (EPI) 76\n3.9 Overarching areas (OVE) 86\n3.10 Psychosis and bipolar disorder (PSY) 88\n3.11 Self-harm and suicide (SUI) 108\niii\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n4. Publication 112\n4.1 Publication and dissemination of the guideline 112\n4.2 Derivative products 112\n4.3 WHO model list of essential medicines (EML) 112\n5. Monitoring and evaluating the impact of the guideline 113\n6. Updating the evidence 114\nReferences 115\nAnnex 1. Contributors to the guideline 130\nAnnex 2. Managing declarations of interest and conflicts of interest 145\nEvidence profiles are available at: https://www.who.int/teams/mental-health-and-substance-use/treatment-care/\nmental-health-gap-action-programme/evidence-centre\niv\nAcknowledgements\nThis World Health Organization (WHO) Mental Health Gap Action Programme (mhGAP) guideline was prepared by\nthe WHO Department of Mental Health and Substance Use under the leadership of Dévora Kestel.\nOverall coordination was provided by Tarun Dua, Neerja Chowdhary and Elaine Brohan, of the WHO Department of\nMental Health and Substance Use.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "stress",
      "relationships",
      "risk_safety",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety 3.1 Alcohol use disorders (ALC) 12\n3.2 Anxiety (ANX) 18\n3.3 Child and adolescent mental disorders (CAMH) 28\n3.4 Conditions related to stress (STR) 46\n3.5 Dementia (DEM) 50\n3.6 Depression (DEP) 58\n3.7 Drug use disorders (DRU) 64\n3.8 Epilepsy and seizures (EPI) 76\n3.9 Overarching areas (OVE) 86\n3.10 Psychosis and bipolar disorder (PSY) 88\n3.11 Self-harm and suicide (SUI) 108\niii\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n4. Publication 112\n4.1 Publication and dissemination of the guideline 112\n4.2 Derivative products 112\n4.3 WHO model list of essential medicines (EML) 112\n5. Monitoring and evaluating the impact of the guideline 113\n6. Updating the evidence 114\nReferences 115\nAnnex 1. Contributors to the guideline 130\nAnnex 2. Managing declarations of interest and conflicts of interest 145\nEvidence profiles are available at: https://www.who.int/teams/mental-health-and-substance-use/treatment-care/\nmental-health-gap-action-programme/evidence-centre\niv\nAcknowledgements\nThis World Health Organization (WHO) Mental Health Gap Action Programme (mhGAP) guideline was prepared by\nthe WHO Department of Mental Health and Substance Use under the leadership of Dévora Kestel.\nOverall coordination was provided by Tarun Dua, Neerja Chowdhary and Elaine Brohan, of the WHO Department of\nMental Health and Substance Use. 3.1 alcohol use disorders (alc) 12\n3.2 lo âu (anx) 18\n3.3 child and adolescent mental disorders (camh) 28\n3.4 conditions related to căng thẳng (str) 46\n3.5 dementia (dem) 50\n3.6 trầm cảm (dep) 58\n3.7 drug use disorders (..."
}